Brief: Arch Biopartners Says Analysis Of Results Of Phase II Trial Of Lead Drug LSALT Peptide Is Ongoing
05/08/2021 12:21
Aug 5 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS INC - ANALYSIS OF RESULTS OF PHASE II
TRIAL OF
ITS LEAD DRUG LSALT PEPTIDE (METABLOK) IS ONGOING
Source text for Eikon: ID:nGNX9x1xdT
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide